[CITATION][C] CKD treatment: time to alter the focus to albuminuria?
D de Zeeuw, R Parekh, S Soman - Advances in chronic kidney disease, 2011 - akdh.org
Slowing renal function loss has not only been focused on ''removing the underlying renal
disease,''but also on modifying the level of these risk markers/factors. In particular, we had
enormous success in implementing antihypertensive therapy and reaching lower targets. 2
In recent decades, we have made another leap forward with a new class of drugs that
intervene in the renin angiotensin aldosterone system (RAAS), such as angiotensin-
converting enzyme inhibitors, angiotensin receptor blockers, aldosterone-antagonist, and …
disease,''but also on modifying the level of these risk markers/factors. In particular, we had
enormous success in implementing antihypertensive therapy and reaching lower targets. 2
In recent decades, we have made another leap forward with a new class of drugs that
intervene in the renin angiotensin aldosterone system (RAAS), such as angiotensin-
converting enzyme inhibitors, angiotensin receptor blockers, aldosterone-antagonist, and …